PL424713A1 - Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome - Google Patents

Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome

Info

Publication number
PL424713A1
PL424713A1 PL424713A PL42471318A PL424713A1 PL 424713 A1 PL424713 A1 PL 424713A1 PL 424713 A PL424713 A PL 424713A PL 42471318 A PL42471318 A PL 42471318A PL 424713 A1 PL424713 A1 PL 424713A1
Authority
PL
Poland
Prior art keywords
inositol
chiro
improving
women
application
Prior art date
Application number
PL424713A
Other languages
Polish (pl)
Other versions
PL238919B1 (en
Inventor
Agata CHODAKOWSKA
Beata ROMAN
Original Assignee
Verco Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verco Spółka Akcyjna filed Critical Verco Spółka Akcyjna
Priority to PL424713A priority Critical patent/PL238919B1/en
Priority to EP19719363.4A priority patent/EP3758798A1/en
Priority to PCT/IB2019/051618 priority patent/WO2019166984A1/en
Publication of PL424713A1 publication Critical patent/PL424713A1/en
Publication of PL238919B1 publication Critical patent/PL238919B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja, zawierająca mio-inozytol i D-chiro-inozytol, do zastosowania w sposobie obniżania masy ciała, poprawy parametrów metabolicznych i hormonalnych oraz poprawy kondycji skóry u kobiet z zespołem policystycznych jajników (PCOS), przy czym mio-inozytol i D-chiro-inozytol są w stosunku wagowym, odpowiednio, 10:1 lub mniejszym.The subject of the application is a composition containing myo-inositol and D-chiro-inositol for use in a method of weight loss, improvement of metabolic and hormonal parameters and improvement of skin condition in women with polycystic ovary syndrome (PCOS), where myo-inositol and D -chiro-inositol are in a weight ratio of 10: 1 or less, respectively.

PL424713A 2018-02-28 2018-02-28 Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome PL238919B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL424713A PL238919B1 (en) 2018-02-28 2018-02-28 Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome
EP19719363.4A EP3758798A1 (en) 2018-02-28 2019-02-28 Composition containing myo-inositol and d-chiro-inositol for use in method of weight reduction, improvement of metabolic and hormonal parameters and improvement of condition of skin in women with polycystic ovary syndrome
PCT/IB2019/051618 WO2019166984A1 (en) 2018-02-28 2019-02-28 Composition containing myo-inositol and d-chiro-inositol for use in method of weight reduction, improvement of metabolic and hormonal parameters and improvement of condition of skin in women with polycystic ovary syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424713A PL238919B1 (en) 2018-02-28 2018-02-28 Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome

Publications (2)

Publication Number Publication Date
PL424713A1 true PL424713A1 (en) 2019-09-09
PL238919B1 PL238919B1 (en) 2021-10-18

Family

ID=67804854

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424713A PL238919B1 (en) 2018-02-28 2018-02-28 Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome

Country Status (3)

Country Link
EP (1) EP3758798A1 (en)
PL (1) PL238919B1 (en)
WO (1) WO2019166984A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4000626A1 (en) * 2020-11-16 2022-05-25 concrete flowers GmbH Pharmaceutical preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906979A (en) 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
JP2006213684A (en) 2005-02-07 2006-08-17 Hokko Chem Ind Co Ltd Composition and health food to be used for ameliorating insulin resistance
ITFI20110252A1 (en) 2011-11-22 2013-05-23 Lo Li Pharma Srl PHARMACEUTICAL COMPOSITION INCLUDING MYO-INOSITOL AND D-CHIRO-INOSITOL.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARTINI P.G., ENDOCRINE AND CLINICAL EFFECTS OF MYO-INOSITOL ADMINISTRATION IN POLYCYSTIC OVARY SYNDROME. A RANDOMIZED STUDY. GYNECOL ENDOCRINOL, 2013 *
GATEVA A., THE USE OF INOSITOL(S) ISOMERS IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: A COMPREHENSIVE REVIEW; GYNECOL ENDOCRINOL, 2018 *
GENAZZANI A.O, INOSITOL AS PUTATIVE INTEGRATIVE TREATMENT FOR PCOS; REPRODUCTIVE BIOMEDICINE ONLINE, 31 December 2016 (2016-12-31) *
MONASTRA, G., COMBINING TREATMENT WITH MYO-INOSITOL AND D-CHIRO­INOSITOL (40:1) IS EFFECTIVE IN RESTORING OVARY FUNCTION AND METABOLIC BALANCE IN PCOS PATIENTS, 2017 *
MUSCOGIURI G., CURRENT INSIGHTS INTO INOSITOL LSOFORMS, MEDITERRANEAN AND KETOGENIC DIETS FOR POLYCYSTIC OVARY SYNDROME: FROM BENCH TO BEDSIDE; CURRENT PHARMACEUTICAL DESIGN, 31 October 2016 (2016-10-31) *

Also Published As

Publication number Publication date
WO2019166984A1 (en) 2019-09-06
EP3758798A1 (en) 2021-01-06
PL238919B1 (en) 2021-10-18

Similar Documents

Publication Publication Date Title
MX2021002046A (en) Cannabis-infused product with controlled cannabinoid profile user experience.
MX2018005639A (en) Seed coating composition.
MX2020007008A (en) Compositions and methods of use of î²-hydroxy-î²-methylbutyrate (hmb) assosiated with intermittent fasting.
BR112018071523A2 (en) sparkling antimicrobial compositions
CL2017002214A1 (en) Combination formulation of tesofensin and beta blocker
PH12020550232A1 (en) Pesticide composition containing thidiazuron and polyglutamic acid
CL2019002514A1 (en) Cosmetic compositions for skin care.
CL2020000267A1 (en) Cosmetic complex for bioactive hydration, cosmetic composition, use and method.
JOP20210029A1 (en) Topical oleaginous compositions
CL2017001860A1 (en) Foaming agent for use in the preparation of edible toppings and a method for the preparation of said agent.
MX2018003086A (en) Composition having reduced residue.
PL424713A1 (en) Composition that contains myo-inositol and D-chiro-inositol, for application in a body weight decreasing method, improving metabolic and hormonal parameters and improving skin condition in women with the polycystic ovary syndrome
PH12020500561A1 (en) Coating for fruit
MX2021006488A (en) Compositions for improving sexual function.
BR112017008245A2 (en) "method for treatment of anti-vibration tuber with reduced amount of cipc"
MX2020007894A (en) Surface-reacted calcium carbonate for modifying the biomechanical properties of the skin.
BR112021016817A2 (en) Cosmetic composition based on a plant product
AR112292A1 (en) COSMETIC COMPLEX FOR BIOACTIVE HYDRATION, COSMETIC COMPOSITION, USE AND METHOD
PH12020551330A1 (en) Insecticidal composition and use thereof
PH12019502031A1 (en) Formulation of stearyl alcohol
WO2020065115A3 (en) Therapeutic uses of atomic quantum clusters
MX2020002401A (en) Edible cannabinoid compositions.
BR112016015977A2 (en) USE OF GIBBERELLIN 7, E, METHODS FOR THINNING AND GROWING DRUPS
BR112016023737A2 (en) ? agricultural composition and water conditioning method?
MX2022009833A (en) Refrigerant compositions and use thereof.